MedTrace Logo

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

NCT00493974 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals. The purpose of this study is to evaluate the effectiveness of zileuton, a medication that is used to control asthma symptoms, at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation, or worsening of COPD symptoms.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Zileuton

Zyflo tablets, 600 mg, 4 times a day

DRUG

Placebo

Placebo 4 x daily

Sponsors & Collaborators

Principal Investigators

  • Prescott Woodruff, MD · University of California at San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493974 on ClinicalTrials.gov